FDA Launches Drug Potency Testing as a $3,900 GLP-1 Program Draws Scrutiny
The Food and Drug Administration has launched a program to test drugs sold at pharmacies and wholesalers, confirming that products contain the listed active ingredient and meet standards for purity and potency. The agency also created an independent council to oversee the postmarketing safety of vaccines, gene therapies and other biologic products. Elsewhere in the week's health news, a woman described a $3,900 GLP-1 program at an island resort, a federal physician-appointee promoted unproven supplements online, and a cruise ship outbreak sickened more than 100 passengers and crew. The stories highlight ongoing questions about product quality, consumer claims and public health response.
What is the FDA drug potency testing program?
The Food and Drug Administration has launched a program to test drugs sold at pharmacies and wholesalers. The goal is to confirm that products contain the active pharmaceutical ingredient listed on the label and that they meet standards for purity and potency. The agency also established an independent council to oversee the postmarketing safety of vaccines, gene therapies and other biologic products, according to a report from Reuters.
What did a patient report about a GLP-1 program?
The week's health coverage also included a firsthand account of a GLP-1 program. A woman described her time at a week-long \
FAQ
- What does the FDA's drug testing program check?
- The program aims to confirm that drugs contain the active pharmaceutical ingredient listed on the label and that they meet standards for purity and potency.
- What does the FDA's new independent council oversee?
- The council oversees the postmarketing safety of vaccines, gene therapies and other biologic products.